GRCL News and Press, Gracell Biotechnologies Inc. From 03/13/23

2023-03-13 07:41:15 ET Gracell Biotechnologies press release ( NASDAQ: GRCL ): Q4 GAAP EPS of -$0.06 beats by $0.07 . As of December 31, 2022, the Company had RMB1,458.2 million (US$211.4 million) in cash and cash equivalents and short-term investments. For f...

Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the second quarter of 2023 after receipt of FDA clearance for Investigational New Drug (IND) application in January 2023 On track to commence Ph...

Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference PR Newswire SAN DIEGO Calif., and SUZHOU and SHANGHAI, China , Feb. 28, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Grac...

Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023 PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , Feb. 27, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell " or ...

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma PR Newswire Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting Fas...

Summary Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. CS Pharmaceuticals entered a $336 million agreement for greater China rights to a PRS inhibitor, Bersipo...

Penny Stocks With News Turning Heads In February 2023 Want to find the best penny stocks to buy now? You’ve got your work cut out for you, and this week was a clear example of how quickly sentiment can change. Thanks to bullishness from the January/February Fed meeting and less-tha...

Gracell Biotechnologies ( NASDAQ: GRCL ) said that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to start a trial of blood cancer drug GC012F. The Chinese company plans to begin a phase 1b/2 trial in the U.S. in Q2 of GC01...

Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma PR Newswire BCMA/CD19 dual-targeting FasTCAR-T GC012F has demonstrated deep responses and favorabl...

Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate PR Newswire BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64 th American S...